Monoclonal antibodies therapies for ovarian cancer

Abstract

Introduction: Despite aggressive debulking surgery, intraperitoneal therapies and the use of new drugs for chemotherapy, patients with ovarian cancer (OC) still have poor prognosis and, therefore, new strategies for its management are needed. Molecular-targeted agents can be considered a new option in drug research. Several antigens related to OC have been isolated and they could be potential target of monoclonal antibodies (mAbs); therefore, different mAbs have been developed and are emerging as new potential OC treatments.

Areas covered: This article aims to review the literature on the use of mAbs in the treatment of OC. The purposes of this manuscript are to offer a brief explanation of the mechanisms of action of mAbs and to help readers in understanding the current role of mAbs in the treatment of OC.

Expert opinion: A deeper knowledge of the molecular biology of OC has brought new developments in targeted therapies. Among these therapies, bevacizumab demonstrated the higher clinical efficacy. Further larger trials are needed to better define the role of the other mAbs in OC treatment. There is a strong need to identify and validate robust biomarkers for a more focused patient selection and for tailoring therapies, optimizing dose and assessing response.

Keywords::

• abagovomab
• bevacizumab
• biomarkers
• catumaxomab
• cetuximab
• farletuzumab
• human milk fat globule 1
• immune system
• ipilimumab
• monoclonal antibodies
• oregovomab
• ovarian cancer
• pertuzumab
• trastuzumab

Notes

This box summarizes key points contained in the article.